VAC2
Non-Small Cell Lung Cancer (NSCLC)
Phase 1Active
Key Facts
Indication
Non-Small Cell Lung Cancer (NSCLC)
Phase
Phase 1
Status
Active
Company
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel allogeneic cell therapies for serious unmet medical needs. Its core technology, the AlloSCOPE™ platform, enables the scalable and consistent production of specialized human cells from pluripotent cell lines. The company is advancing multiple programs, including OPC1 for spinal cord injury and OpRegen for geographic atrophy, and has established a significant collaboration with Genentech. Lineage is publicly traded on the NYSE American under the ticker LCTX.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| NBTXR3 + anti-PD1 | Nanobiotix | Phase 1 |
| TTFields | Novocure | Phase 3 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1/2 |
| TG6050 | Transgene SA | Preclinical |
| Monalizumab (IPH2201) | Innate Pharma | Phase 3 |
| Plinabulin | BeyondSpring | Phase 2/3 |
| PD1-Vaxx (IMU-201) | Imugene | Phase 1 |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |
| Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab) | Genprex | Phase 1/2 |
| ABD-3001 | Advanced Biodesign | Phase 1 |